Rohit Aggarwal

Long-term Safety and Efficacy of Dazukibart in Dermatomyositis: Combined Phase 2 Results from Double-blind and Open-Label Extension Studies

Objective To evaluate long-term safety and efficacy of dazukibart, a novel anti-interferon beta monoclonal antibody, in adults with moderate-to-severe dermatomyositis (DM). Methods Participants from two cohorts of DM (skin-predominant, SP and muscle-predominant, MP), completing a...

Clinical Meaningfulness and Improvement Thresholds of Myositis Core Set Measures: Association with Patient-Reported Outcomes

Objective The study aimed to evaluate the clinical meaningfulness and improvement thresholds of the myositis core set measures (CSMs) of disease activity in idiopathic inflammatory myopathies (IIM), emphasizing associations with patient-reported outcome measures (PROMs). Methods...